Guided Therapeutics Achieves Record Quarterly Revenue

Jan 12, 2016, GTHP OTC Disclosure & News Service Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today fourth quarter sales revenue for the LuViva® Advanced Cervical Scan was the highest since the launch of the product. LuViva product revenue was approximately $276,000 for the fourth quarter of 2015 versus approximately $183,000 for the same period of 2014, an increase of about 51%. Total sales for the year ended December 31, 2015 is expected to be approximately $665,000 compared to $795,000 for all of 2014. The quarter does not reflect a large expected shipment to Turkey that is now planned for Q1 2016. Had that shipment been recognized in 4Q, the company would have recorded an annual revenue increase in 2015. “Sales for the fourth quarter are very encouraging and reflect a growing base of countries where LuViva is becoming more established,” said Gene Cartwright, CEO and Presiden


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: